Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

PRW - Pro-Pharmaceuticals Inc.

619 Posts
Pagina: «« 1 ... 26 27 28 29 30 31 »» | Laatste | Omlaag ↓
  2. [verwijderd] 24 juli 2007 15:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Jommeke schreef:

    Pro-Pharmaceuticals Submits Plan of Compliance to Amex

    biz.yahoo.com/bw/070724/2007072400525...
    benieuwd wat hier uitkomt, indien ze op amex blijven zou de koers ms weer wat herstellen, anders krijgen we een flinke dip. Weet iemand wat timetable wanneer uitspraak komt delisting ja of nee?
  6. [verwijderd] 15 september 2007 20:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    14-Sep-2007

    Financial Statements and Exhibits

    Item 8.01. Other Events, Financial Statements and Exhibits
    On September 13, 2007, the Company received notice from American Stock Exchange ("Amex") Staff that the Amex has accepted the Company's plan of compliance and granted the Company an extension until October 13, 2008 to regain compliance with the continued listing standards. The Company will be subject to periodic review by Amex Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being de-listed from the American Stock Exchange.

    On June 22, 2007, the Company received notice from the Amex Staff indicating that the Company was below certain of the Amex's continued listing standards due to losses in two of its last three years with stockholders' equity below $2 million as set forth in Section 1003 (a)(i) of the Amex Company Guide. As previously announced, the Company was afforded an opportunity to submit a plan of compliance and presented its plan to the Amex on July 23rd.

    Item 9.01 Financial Statements and Exhibits.

    (c) Exhibits
    99.1 News release of Pro-Pharmaceuticals, Inc. dated September 14, 2007.


  7. [verwijderd] 15 september 2007 20:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
    New User? Sign UpFinance Home -Help


    Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesSymbol LookupFinance Search



    Press Release Source: Pro-Pharmaceuticals, Inc.

    Amex Accepts Pro-Pharmaceuticals Plan of Compliance
    Friday September 14, 7:00 am ET

    NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a company "Advancing Drugs Through Glycoscience®", today announced it received notice from American Stock Exchange ("Amex") Staff that the Amex has accepted the Company's plan of compliance and granted the Company an extension until October 13, 2008 to regain compliance with the continued listing standards. The Company will be subject to periodic review by Amex Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being de-listed from the American Stock Exchange.

    On June 22, 2007, the Company received notice from the Amex Staff indicating that the Company was below certain of the Amex's continued listing standards due to losses in two of its last three years with stockholders' equity below $2 million as set forth in Section 1003 (a)(i) of the Amex Company Guide. As previously announced, the Company was afforded an opportunity to submit a plan of compliance and presented its plan to the Amex on July 23rd.

    Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience®

    Pro-Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. The Company's initial focus is the development of a new generation of anti-cancer treatments using polymers with the intent of enhancing the safety and efficacy of chemotherapy agents. The Company's technology also is directed at "rescuing" drugs that were shelved for toxicity or "half-life" issues; increasing the solubility of existing drugs, and developing polymers as new chemical entities. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.

    FORWARD LOOKING STATEMENTS: Any statements in this news release about this or future financings, expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the expected closing of the private placement and the anticipated use of proceeds. Such factors include uncertainties as to the utility and market for the Company's potential products; uncertainties associated with pre-clinical and clinical trials of the Company's product candidates; the Company's limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of its potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of its proprietary technology; compliance with and change of government regulation of the Company's activities, facilities and personnel; uncertainties as to the extent of reimbursement for the Company's potential products by government and private health insurers, uncertainties as to maintaining our listing on the American Stock Exchange, and the Company's history of operating losses and accumulated deficit. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. More information about those risks and uncertainties is contained in the Company's quarterly or annual report, Form 8-K and in the Company's other reports filed with the Securities and Exchange Commission. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

    DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals.

    Contact:
    Pro-Pharmaceuticals, Inc.
    Anthony D. Squeglia, 617-559-0033
    squeglia@pro-pharmaceuticals.com

  11. [verwijderd] 22 september 2007 17:08

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    wie zitten hier in of zijn er vandaag ingestapt??
    wat verwachten jullie??
    Ik zit we nog in Welsh. Koers is bijna verdubbeld deze week. Ik blijf lekker zitten. Let maar op, er komt nog meer!
  19. [verwijderd] 11 oktober 2007 19:58

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pro-Pharmaceuticals Reports 43% Response Rate in Colorectal Trial
    Thursday October 11, 7:00 am ET
    No Hematological or Gastrointestinal Serious Adverse Events Reported

    NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a company "Advancing Drugs Through Glycoscience®", today reported that three of seven (43%) evaluable patients in its Phase II colorectal cancer trial have experienced tumor shrinkage of greater than 30%, a partial response according to Response Evaluation Criteria for Solid Tumors (RECIST). In addition, none of the patients in the trial have experienced hematological or gastrointestinal severe adverse events (SAEs) of grade 3 or higher. SAEs generally result in life threatening events, inpatient hospitalization, persistent or significant disability, or death.
    ADVERTISEMENT


    The Phase II trial is for first-line treatment of patients with metastatic, unresectable colorectal cancer who are unable to tolerate intensive chemotherapy. The Simon two-stage designed study is an open-label, multi-center trial with a regimen of DAVANAT® in combination with 5-Fluorouricil, Leucovorin and Avastin®. The primary objective of the trial is a complete or partial tumor response in 34% (14 of 41) of evaluable patients. Progression-free survival is a secondary endpoint. To date, eight patients have been dosed. Six clinical sites are recruiting patients. Additional information on the clinical trial and participating clinical sites can be found at www.clinicaltrials.gov, key word: DAVANAT®.

    "We are encouraged by the promising early data from our colorectal cancer clinical trial," said David Platt, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals, Inc. "Our goal is to improve the clinical benefit for patients by reducing the toxicity and improving the efficacy of chemotherapy regimens used to treat colorectal cancer. The need to improve drug therapies, particularly anti-cancer agents, is significant and represents a large market opportunity
  20. [verwijderd] 11 oktober 2007 20:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    hoor niemand meer over dit aandeel , vandaag weer super gestegen nu 0,89
    Super gedaald vandaag, nu -/- 25% is zelfs even -/- 40% geweest.

    Teleurgesteld in de resultaten, terwijl voor patienten 43% kans op afname tumor denk ik een opsteker is in ontwikkelingen.
    Soms gaan beleggen en menselijke verwachtingen (lees hoop) niet samen

    Wel triest op zich !!!

    Jay (gelukkig gezond)
619 Posts
Pagina: «« 1 ... 26 27 28 29 30 31 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.122
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.199
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.863
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.843
Aedifica 3 926
Aegon 3.258 323.084
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.300
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 423
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.937
AMG 971 134.427
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.994
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.258
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.952
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449

Macro & Bedrijfsagenda

  1. 31 maart

    1. Inkoopmanagersindex industrie en diensten maart (Chi)
    2. Importprijzen februari (Dld)
    3. Detailhandelsverkopen februari (Dld)
    4. Inflatie maart vlpg (Dld)
    5. Inkoopmanagersindex Chicago maart (VS)

  2. 01 april

    1. Tankan index eerste kwartaal (Jap)
    2. Inkoopmanagersindex industrie maart def. (Jap)
    3. Inkoopmanagersindex industrie Caixin maart (Chi)
    4. Reserve Bank of Australia rentebesluit (Aus)
    5. Omzet detailhandel februari (NL)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda